AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
441.00B
Market cap441.00B
Price-Earnings ratio
70.33
Price-Earnings ratio70.33
Dividend yield
2.75%
Dividend yield2.75%
Average volume
5.12M
Average volume5.12M
High today
$251.80
High today$251.80
Low today
$247.68
Low today$247.68
Open price
$250.60
Open price$250.60
Volume
4.20M
Volume4.20M
52 Week high
$267.47
52 Week high$267.47
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

As of today, AbbVie(ABBV) shares are valued at $249.46. The company's market cap stands at 441B, with a P/E ratio of 70.33 and a dividend yield of 2.75%.

During the trading session on 2026-08-16, AbbVie(ABBV) shares reached a daily high of $251.80 and a low of $247.68. At a current price of $249.46, the stock is +0.7% higher than the low and still -0.9% under the high.

Trading volume for AbbVie(ABBV) stock has reached 4.2M, versus its average volume of 5.12M.

The stock's 52-week range extends from a low of $190.75 to a high of $267.47.

The stock's 52-week range extends from a low of $190.75 to a high of $267.47.

ABBV News

The Motley Fool 5h
Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year - The Motley Fool

...

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year - The Motley Fool
Simply Wall St 5h
What Does AbbVie Need To Prove After Its Phase 3 Setback?

AbbVie (NYSE:ABBV) and Genmab reported that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in diffuse large B-cell lymphoma did not meet its overall survival p...

What Does AbbVie Need To Prove After Its Phase 3 Setback?
Seeking Alpha 2d
Glenview adds Eli Lilly, AbbVie, trims CVS, AMAT, among top Q2 trades

Glenview Capital Management took new equity positions in Eli Lilly (LLY), with nearly 58K shares, and AbbVie (ABBV), with ~149K shares, according to the hedge f...

Glenview adds Eli Lilly, AbbVie, trims CVS, AMAT, among top Q2 trades

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More ABBV News

Nasdaq 2d
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high...

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 2d
AbbVie Steps Deeper Into Alzheimer’s: What the ABBV-1758 Trial Means for Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

TipRanks 2d
AbbVie Wraps Real‑World China Study on Upadacitinib in Atopic Dermatitis: What Investors Should Watch

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

Simply Wall St 3d
AbbVie Lifted 2026 Guidance, Is The Upside Already Priced In?

AbbVie (ABBV) just raised its 2026 revenue and earnings guidance, alongside solid second quarter numbers and fresh regulatory progress, putting the stock’s rece...

AbbVie Lifted 2026 Guidance, Is The Upside Already Priced In?
24/7 Wall St. 4d
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

want a stake in closing that gap. See the offering → (sponsor) Goldman Sachs projects AI demand will exceed compute center capacity for years to come. One Sky...

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
TipRanks 4d
AbbVie’s BOTOX Jawline Trial Wraps Up: What the Masseter Study Means for ABBV Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

TipRanks 4d
AbbVie’s Venetoclax Combo in High-Risk MDS: What a Fresh Trial Update Signals for Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.